Payment overview · 2025
General Payments
$790.32
32 reported records · 13 companies
Healthcare provider profile · identity verified
Mumtaz Husain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST LIVERPOOL, OH · NPI 1295751113
Verified facts
What the public records show
CMS Open Payments records show Mumtaz Husain, MD received $790.32 in general payments during 2025 across 32 reported records.
Shockwave Medical, Inc accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $168.42 | 21.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.80 | 14.3% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.96 | 9.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.43 | 9.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $76.06 | 9.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $68.91 | 8.7% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $42.33 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.58 | 5.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.33 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.89 | 4.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.33 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.67 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.61 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $790.32 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $168.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $77.96 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.06 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68.91 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.95 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $42.33 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.33 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 154 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
154 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
263 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 461 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 65 |
| Omeprazole | Omeprazole | 321 | 68 |
| Eliquis | Apixaban | 263 | 34 |
| Mirtazapine | Mirtazapine | 213 | 38 |
| Metformin Hcl | Metformin Hcl | 203 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 47 |
| Potassium Chloride | Potassium Chloride | 187 | 39 |
| Memantine Hcl | Memantine Hcl | 172 | 26 |
| Lisinopril | Lisinopril | 169 | 43 |
| Mounjaro | Tirzepatide | 154 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 35 |
| Furosemide | Furosemide | 135 | 31 |
| Famotidine | Famotidine | 129 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 24 |
| Glimepiride | Glimepiride | 121 | 29 |
| Bumetanide | Bumetanide | 120 | 28 |
| Carvedilol | Carvedilol | 119 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 33 |
| Rivastigmine | Rivastigmine Tartrate | 119 | 20 |
| Sertraline Hcl | Sertraline Hcl | 117 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 31 |
| Losartan Potassium | Losartan Potassium | 112 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 20 |
| Tramadol Hcl | Tramadol Hcl | 94 | 13 |
| Alendronate Sodium | Alendronate Sodium | 87 | 22 |
| Clonazepam | Clonazepam | 87 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 20 |
| Jardiance | Empagliflozin | 80 | 13 |
| Simvastatin | Simvastatin | 80 | 12 |
| Trazodone Hcl | Trazodone Hcl | 80 | 23 |
| Celecoxib | Celecoxib | 76 | 21 |
| Xarelto | Rivaroxaban | 75 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 16 |
| Allopurinol | Allopurinol | 67 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 63 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | 12 |
| Lorazepam | Lorazepam | 62 | 23 |
| Montelukast Sodium | Montelukast Sodium | 60 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 60 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 58 | 14 |
| Prednisone | Prednisone | 58 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | suppressed |
| Alprazolam | Alprazolam | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Atenolol | Atenolol | 50 | 12 |
| Fentanyl | Fentanyl | 49 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 46 | 13 |
| Atomoxetine Hcl | Atomoxetine Hcl | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Azithromycin | Azithromycin | 34 | 29 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Ibu | Ibuprofen | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cimetidine | Cimetidine | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $790.32 · 32 records | Shockwave Medical, Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VOQUEZNA, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error